IBDEI2GM ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39282,0)
 ;;=E89.6^^152^1993^29
 ;;^UTILITY(U,$J,358.3,39282,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39282,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,39282,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,39282,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,39283,0)
 ;;=L68.0^^152^1993^6
 ;;^UTILITY(U,$J,358.3,39283,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39283,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,39283,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,39283,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,39284,0)
 ;;=M80.00XA^^152^1993^2
 ;;^UTILITY(U,$J,358.3,39284,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39284,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,39284,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,39284,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,39285,0)
 ;;=M81.0^^152^1993^3
 ;;^UTILITY(U,$J,358.3,39285,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39285,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,39285,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,39285,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,39286,0)
 ;;=M85.80^^152^1993^26
 ;;^UTILITY(U,$J,358.3,39286,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39286,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,39286,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,39286,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,39287,0)
 ;;=N62.^^152^1993^5
 ;;^UTILITY(U,$J,358.3,39287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39287,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,39287,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,39287,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,39288,0)
 ;;=E66.3^^152^1993^27
 ;;^UTILITY(U,$J,358.3,39288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39288,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,39288,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,39288,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,39289,0)
 ;;=E89.1^^152^1993^31
 ;;^UTILITY(U,$J,358.3,39289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39289,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,39289,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,39289,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,39290,0)
 ;;=R73.03^^152^1993^33
 ;;^UTILITY(U,$J,358.3,39290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39290,1,3,0)
 ;;=3^Pre-Diabetes
 ;;^UTILITY(U,$J,358.3,39290,1,4,0)
 ;;=4^R73.03
 ;;^UTILITY(U,$J,358.3,39290,2)
 ;;=^8295662
 ;;^UTILITY(U,$J,358.3,39291,0)
 ;;=E73.9^^152^1993^18
 ;;^UTILITY(U,$J,358.3,39291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39291,1,3,0)
 ;;=3^Lactose Intolerance,Unspec
 ;;^UTILITY(U,$J,358.3,39291,1,4,0)
 ;;=4^E73.9
 ;;^UTILITY(U,$J,358.3,39291,2)
 ;;=^5002914
 ;;^UTILITY(U,$J,358.3,39292,0)
 ;;=H40.9^^152^1994^11
 ;;^UTILITY(U,$J,358.3,39292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39292,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,39292,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,39292,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,39293,0)
 ;;=H26.9^^152^1994^7
 ;;^UTILITY(U,$J,358.3,39293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39293,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,39293,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,39293,2)
 ;;=^5005363
 ;;^UTILITY(U,$J,358.3,39294,0)
 ;;=H10.9^^152^1994^10
 ;;^UTILITY(U,$J,358.3,39294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39294,1,3,0)
 ;;=3^Conjunctivitis,Unspec
